Clinical Trials Browser

Phase 2 × OTHER × MEK inhibitor I × Clear all

NCT06322095 2024-10-01

A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors

Phase 2 Recruiting

Other solid neoplasm

Patients With Advanced Solid Tumor